The Johns Hopkins Alzheimer's Disease Research Center (JHADRC) is an integrated program of investigators whose overarching goal is to improve understanding of the earliest phases of AD and to expand therapeutic approaches. The overall scientific focus of the JHADRC is on the earliest stages of AD and related disorders in humans and in model systems, through characterizing the earliest clinical and pathophysiological processes in humans, and by identifying cellular and molecular events that contribute to the abnormalities in model systems that capture aspects of the human disorders. We also focus efforts on improving care of patients in the symptomatic phases of disease. We have made substantial progress with these research goals during the current funding cycle (which is described below) and propose to continue and expand this work in the next funding cycle. The Center consists of 5 Cores: (1) the Administrative Core (Core A), (2) the Clinical Core (Core B), (3) the Data Management of Statistics Core (Core C), (4) the Neuropathology Core (Core D), and (5) the Outreach, Recruitment and Education Core (Core E). In this application we are proposing 3 new projects: (1) Project 1, to be led by Dr. Arnold Bakker (Assistant Professor of Psychiatry), will examine alterations in brain connectivity in MCI patients and subjects with subjective memory concerns vs. controls, and their relationship to AD CSF biomarkers. (2) Project 2, to be led by Dr. Philip Wong (Professor of Pathology and Neuroscience), will utilize a new mouse model of AD that closely mimics the human disease (by exhibiting both amyloidosis and tauopathy, and demonstrating neuronal loss) to test the hypothesis that amyloid induces tau aggregation to initiate synaptic dysfunction and promote loss of neurons. (3) Project 3, to be led by Dr. Richard Huganir (Professor and Chair of Neuroscience) will examine the impact of excitatory neurotransmitters and neuronal plasticity on synaptic alterations in the earliest phases of AD.

Public Health Relevance

The Johns Hopkins Alzheimer's Disease Research Center is an integrated program aimed at finding improved treatments for patients with Alzheimer disease and related disorders. Complimentary activities within the center include clinical and basic research studies that incorporate state-of-the art methodologies, and contribute significantly to national programs. We are dedicated to training the next generation of investigators and to reaching out to the community to improve understanding about these diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG005146-32
Application #
8848594
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (J1))
Program Officer
Phelps, Creighton H
Project Start
1997-07-15
Project End
2020-03-31
Budget Start
2015-05-01
Budget End
2016-03-31
Support Year
32
Fiscal Year
2015
Total Cost
$1,881,193
Indirect Cost
$716,086
Name
Johns Hopkins University
Department
Pathology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar S et al. (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci U S A 115:1635-1640
Nicolas, Aude (see original citation for additional authors) (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97:1268-1283.e6
Bouhrara, Mustapha; Reiter, David A; Bergeron, Christopher M et al. (2018) Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimers Dement 14:998-1004
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Varma, Vijay R; Oommen, Anup M; Varma, Sudhir et al. (2018) Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med 15:e1002482
Wong, Dean F; Comley, Robert A; Kuwabara, Hiroto et al. (2018) Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects. J Nucl Med 59:1869-1876
Soldan, Anja; Pettigrew, Corinne; Albert, Marilyn (2018) Evaluating Cognitive Reserve Through the Prism of Preclinical Alzheimer Disease. Psychiatr Clin North Am 41:65-77
Guerreiro, Rita; Ross, Owen A; Kun-Rodrigues, Celia et al. (2018) Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol 17:64-74
Zhou, Zilu; Wang, Weixin; Wang, Li-San et al. (2018) Integrative DNA copy number detection and genotyping from sequencing and array-based platforms. Bioinformatics 34:2349-2355
Ye, Chenfei; Ma, Ting; Wu, Dan et al. (2018) Atlas pre-selection strategies to enhance the efficiency and accuracy of multi-atlas brain segmentation tools. PLoS One 13:e0200294

Showing the most recent 10 out of 830 publications